Antioxidants and endothelial dysfunction in hyperlipidemia

Current Hypertension Reports

Volumn 3, Issue 1, 2001, Pages 53-60

  Warnholtz, Ascan ^a   Mollnau, Hanke ^a   Oelze, Mathias ^a   Wendt, Maria ^a   Münzel, Thomas ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT;

ANIMAL; HUMAN; HYPERLIPIDEMIA; PATHOPHYSIOLOGY; REVIEW; VASCULAR ENDOTHELIUM;

ANIMALS; ANTIOXIDANTS; ENDOTHELIUM, VASCULAR; HUMANS; HYPERLIPIDEMIAS;

EID: 0035257403     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-001-0081-z     Document Type: Article

References (62)

1. Schachinger V, Britten MB, Zeiher AM: Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000, 101: 1899-1906.
2. Suwaidi JA, Hamasaki S, Higano ST, et al.: Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000, 101: 948-954.
3. Palmer RM, Ferrige AG, Moncada S: Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987, 327: 524-526.
4. Myers PR, Minor RL Jr, Guerra R Jr, et al.: Vasor elaxa nt properties of the endothelium-derived relaxing factor more closely resemble S-nitrosocysteine than nitric oxide. Nature 1990, 345: 161-163.
5. Munzel T, Heitzer T, Harrison DG: The physiology and pathophysiology of the nitric oxide/superoxide system. Herz 1997, 22: 158-172.
6. Gryglewski RJ, Palmer RMJ, Moncada S: Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature 1986, 320: 454-456.
7. Beckman JS, Beckman TW, Chen J, et al.: Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci U S A 1990, 87: 1620-1624.
8. Freiman PC, Mitchell GC, Heistad DD, et al.: Atherosclerosis impairs endothelium-dependent vascular relaxation to acetylcholine and thrombin in primates. Circ Res 1986, 58: 783-789.
9. Ludmer PL, Selwyn AP, Shook TL, et al.: Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 1986, 315: 1046-1051.
10. Zeiher AM, Drexler H, Wollschlager H, et al.: Modulation of coronary vasomotor tone in humans. Progressive endothelial dysfunction with different early stages of coronary atherosclerosis. Circulation 1991, 83: 391-401.
11. Min: Diet-induced atherosclerosis increases the release of nitrogen oxides from rabbit aorta. J Clin Invest 1990, 86: 2109-2116.
12. Mugge A, Elwell JH, Peterson TE, et al.: Chronic treatment with polyethylene-glycolated superoxide dismutase partially restores endothelium-dependent vascular relaxations in cholesterol-fed rabbits. Circ Res 1991, 69: 1293-1300.
13. White CR, Brock TA, Chang LY, et al.: Superoxide and peroxynitrite in atherosclerosis. Proc Natl Acad Sci U S A 1994, 91: 1044-1048.
14. Ohara Y, Peterson TE, Harrison DG: Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest 1993, 91: 2546-2551.
15. Miller FJ Jr, Gutterman DD, Rios CD, et al.: Superoxide production in vascular smooth muscle contributes to oxidative stress and impaired relaxation in atherosclerosis. Circ Res 1998, 82: 1298-1305.
16. White CR, Darley-Usmar V, Berrington WR, et al.: Circulating plasma xanthine oxidase contributes to vascular dysfunction in hypercholesterolemic rabbits. Proc Natl Acad Sci U S A 1996, 93: 8745-8749.
17. Warnholtz A, Nickenig G, Schulz E, et al.: Increased NADH-oxidase- mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin-angiotensin system. Circulation 1999, 99: 2027-2033.
18. Guzik TJ, West NE, Black E, et al.: Vascular superoxide production by NAD (P) H oxidase: association with endothelial dysfunction and clinical risk factors. Circ Res 2000, 86: E85-E90.
19. Griendling KK, Sorescu D, Ushio-Fukai M: NAD (P) H oxidase: role in cardiovascular biology and disease. Circ Res 2000, 86: 494-501.
20. Xia Y, Tsai AL, Berka V, et al.: Superoxide generation from endothelial nitric-oxide synthase. A Ca2+/calmodulindependent and tetrahydrobiopterin regulatory process. J Biol Chem 1998, 273: 25804-25808.
21. Vasquez-Vivar J, Kalyanaraman B, Martasek P, et al.: Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc Natl Acad Sci U S A 1998, 95: 9220-9225.
22. Vergnani L, Hatrik S, Ricci F, et al.: Effect of native and oxidized low-density lipoprotein on endothelial nitric oxide and superoxide production: key role of L-arginine availability. Circulation 2000, 101: 1261-1266.
23. Milstien S, Katusic Z: Oxidation of tetrahydrobiopterin by peroxynitrite: implications for vascular endothelial function. Biochem Biophys Res Commun 1999, 263: 681-684.
24. Tsikas D, Boger RH, Sandmann J, et al.: Endogenous nitric oxide synthase inhibitors are responsible for the L-arginine paradox. FEBS Lett 2000, 478: 1-3.
25. Boger RH, Bode-Boger SM, Szuba A, et al.: Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 1998, 98: 1842-1847.
26. Hambrecht R, Wolf A, Gielen S, et al.: Effect of exercise on coronary endothelial function in patients with coronary artery disease [see comments]. N Engl J Med 2000, 342: 454-460.
27. Ohara Y, Peterson TE, Sayegh HS, et al.: Dietary correction of hypercholesterolemia in the rabbit normalizes endothelial superoxide anion production. Circulation 1995, 92: 898-903.
28. Treasure CB, Klein JL, Weintraub WS: Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease [see comments]. N Engl J Med 1995, 332: 481-487.
29. Anderson TJ, Meredith I, Yeung AC, et al.: The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion [see comments]. N Engl J Med 1995, 332: 488-494.
30. Vita JA, Yeung AC, Winniford M, et al.: Effect of cholesterollowering therapy on coronary endothelial vasomotor function in patients with coronary artery disease [see comments]. Circulation 2000, 102: 846-851.
31. Laufs U, Liao JK: Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem 1998, 273: 24266-24271.
32. Wagner AH, Kohler T, Ruckschloss U, et al.: Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol 2000, 20: 61-69.
33. Frei B, England L, Ames BN: Ascorbate is an outstanding antioxidant in human blood plasma. Proc Natl Acad Sci 1989, 86: 6377-3781.
34. Levine GN, Frei B, Koulouris SN, et al.: Ascorbic acid reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation 1996, 93: 1107-1113.
35. Ting HH, Timimi FK, Boles KS, et al.: Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus. J Clin Invest 1996, 97: 22-28.
36. Heitzer T, Just H, Munzel T: Antioxidant vitamin C improves endothelial dysfunction in chronic smokers. Circulation 1996, 94: 6-9.
37. Solzbach U, Hornig B, Jeserich M, et al.: Vitamin C improves endothelial dysfunction of epicardial coronary arteries in hypertensive patients [see comments]. Circulation 1997, 96: 1513-1519.
38. Huang A, Venema RC, Vita JA, et al.: Ascorbic acid enhances endothelial nitric oxide production in a tetrahydrobiopterindependent manner [abstract]. Circulation 1999, 100: I-702.
39. Stephens NG, Parsons A, Schofield PM, et al.: Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS) [see comments]. Lancet 1996, 347: 781-786.
40. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group [see comments]. N Engl J Med 1994, 330: 1029-1035.
41. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico [see comments]. Lancet 1999, 354: 447-455.
42. Vitamin E supplementation and cardiovascular events in high-risk patients. N Engl J Med 2000, 342: 154-160.
43. Thomas SR, Stocker R: Molecular action of vitamin E in lipoprotein oxidation: implications for atherosclerosis [in process citation]. Free Radic Biol Med 2000, 28: 1795-1805.
44. Keaney JF, Jr., Gaziano JM, Xu A, et al.: Low-dose alpha-tocopherol improves and high-dose alpha-tocopherol worsens endothelial vasodilator function in cholesterol-fed rabbits. J Clin Invest 1994, 93: 844-851.
45. Pieper GM: Acute amelioration of diabetic endothelial dysfunction with a derivative of the nitric oxide synthase cofactor tetrahydrobiopterin. J Cardiovasc Pharmacol 1997, 29: 8-15.
46. Cosentino F, Patton S, D'Uscio LV, et al.: Tetrahydrobiopterin alters superoxide and nitric oxide release in prehypertensive rats. J Clin Invest 1998, 101: 1530-1537.
47. Stroes E, Kastelein J, Cosentino F, et al.: Tetrahydrobiopterin restores endothelial function in hypercholesterolemia. J Clin Invest 1997, 99: 41-46.
48. Heitzer T, Brockhoff C, Mayer B, et al.: Tetrahydrobiopterin improves endothelium-dependent vasodilation in chronic smokers: evidence for a dysfunctional nitric oxide synthase. Circ Res 2000, 86: E36-E41.
49. Beckman JS, Ye ZY, Anderson PG, et al.: Extensive nitration of protein tyrosines in human atherosclerosis detected by immunohistochemistry. Biolog Chem Hoppe-Seyler 1994, 375: 81-88.
50. Petruzzelli S, Puntoni R, Mimotti P, et al.: Plasma 3-nitrotyrosine in cigarette smokers. Am J Respir Crit Care Med 1997, 156: 1902-1907.
51. Pritchard KA, Jr., Groszek L, Smalley DM, et al.: Native lowdensity lipoprotein increases endothelial cell nitric oxide synthase generation of superoxide anion. Circ Res 1995, 77: 510-518.
52. Boger RH, Bode-Boger SM, Brandes RP, et al.: Dietary L-arginine reduces the progression of atherosclerosis in cholesterol-fed rabbits: comparison with lovastatin. Circulation 1997, 96: 1282-1290.
53. Boger RH, Bode-Boger SM, Phivthong-ngam L, et al.: Dietary L-arginine and alpha-tocopherol reduce vascular oxidative stress and preserve endothelial function in hypercholesterolemic rabbits via different mechanisms. Atherosclerosis 1998, 141: 31-43.
54. Drexler H, Zeiher AM, Meinzer K, et al.: Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine. Lancet 1991, 338: 1546-1550.
55. Becker RH, Wiemer G, Linz W: Preservation of endothelial function by ramipril in rabbits on a long-term atherogenic diet. J Cardiovasc Pharmacol 1991, 18: S110-S115.
56. Mancini GB, Henry GC, Macaya C, et al.: Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study [see comments]. Circulation 1996, 94: 258-265.
57. Prasad A, Tupas-Habib T, Schenke WH, et al.: Acute and chronic angiotensin-1 receptor antagonism reverses endothelial dysfunction in atherosclerosis [in process citation]. Circulation 2000, 101: 2349-2354.
58. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000, 342: 145-153.
59. Nickenig G, Sachinidis A, Michaelsen F, et al.: Upregulation of vascular angiotensin II receptor gene expression by lowdensity lipoprotein in vascular smooth muscle cells. Circulation 1997, 95: 473-478.
60. Nickenig G, Bohm M: Regulation of the angiotensin AT1 receptor expression by hypercholesterolemia. Eur J Med Res 1997, 2: 285-289.
61. Nickenig G, Baumer AT, Temur Y, et al.: Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation 1999, 100: 2131-2134.
62. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group [see comments]. N Engl J Med 1998, 339: 1349-1357.